0000899243-20-033903.txt : 20201215 0000899243-20-033903.hdr.sgml : 20201215 20201215164724 ACCESSION NUMBER: 0000899243-20-033903 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201211 FILED AS OF DATE: 20201215 DATE AS OF CHANGE: 20201215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRATTON DOUGLAS K CENTRAL INDEX KEY: 0001281933 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 201390089 MAIL ADDRESS: STREET 1: 201 MAIN STREET STREET 2: SUITE 1900 CITY: FORT WORTH STATE: TX ZIP: 76102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Neuro Line Partners LP CENTRAL INDEX KEY: 0001723842 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 201390090 BUSINESS ADDRESS: STREET 1: 201 MAIN STREET STREET 2: SUITE 1900 CITY: FORT WORTH STATE: TX ZIP: 76102 BUSINESS PHONE: 817.339.7600 MAIL ADDRESS: STREET 1: 201 MAIN STREET STREET 2: SUITE 1900 CITY: FORT WORTH STATE: TX ZIP: 76102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bratton Capital Management, L.P. CENTRAL INDEX KEY: 0001723787 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 201390091 BUSINESS ADDRESS: STREET 1: 201 MAIN STREET STREET 2: SUITE 1900 CITY: FORT WORTH STATE: TX ZIP: 76102 BUSINESS PHONE: 817.339.7600 MAIL ADDRESS: STREET 1: 201 MAIN STREET STREET 2: SUITE 1900 CITY: FORT WORTH STATE: TX ZIP: 76102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bratton Capital Inc. CENTRAL INDEX KEY: 0001723783 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 201390092 BUSINESS ADDRESS: STREET 1: 201 MAIN STREET STREET 2: SUITE 1900 CITY: FORT WORTH STATE: TX ZIP: 76102 BUSINESS PHONE: 817.339.7600 MAIL ADDRESS: STREET 1: 201 MAIN STREET STREET 2: SUITE 1900 CITY: FORT WORTH STATE: TX ZIP: 76102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-11 0 0001714899 Denali Therapeutics Inc. DNLI 0001281933 BRATTON DOUGLAS K 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001723842 Neuro Line Partners LP 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001723787 Bratton Capital Management, L.P. 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001723783 Bratton Capital Inc. 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 Common Stock 2020-12-11 4 S 0 46799 80.0539 D 401236 I By Neuro Line Partners, L.P. Common Stock 2020-12-14 4 S 0 16949 80.3454 D 384287 I By Neuro Line Partners, L.P. Common Stock 2020-12-14 4 S 0 876 81.1281 D 383411 I By Neuro Line Partners, L.P. Common Stock 12201634 I By AKDL, L.P. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.83 to $80.31, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4) and (5) to this Form 4. These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.10 to $80.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.115 to $81.18, inclusive. These shares of common stock of the Issuer are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. (Continued from Footnote 6) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. DOUGLAS K. BRATTON, Name: /s/ Douglas K. Bratton 2020-12-15 NEURO LINE PARTNERS, L.P., By: Bratton Capital Management, L.P., its general partner, By: Bratton Capital, Inc., its general partner, Name: /s/ Douglas K. Bratton, Title: Sole Director 2020-12-15 BRATTON CAPITAL MANAGEMENT, L.P., By: Bratton Capital, Inc., its general partner, Name: /s/ Douglas K. Bratton, Title: Sole Director 2020-12-15 BRATTON CAPITAL, INC., Name: /s/ Douglas K. Bratton, Title: Sole Director 2020-12-15 EX-99.1 2 attachment1.htm EX-99.1 DOCUMENT

                                                                    Exhibit 99.1


                         Form 4 Joint Filer Information


Name:                                          Neuro Line Partners, L.P.

Address:                                       201 Main Street, Suite 1900
                                               Fort Worth, TX 76102

Date of Event Requiring Statement:             12/11/2020


Name:                                          Bratton Capital Management, L.P.

Address:                                       201 Main Street, Suite 1900
                                               Fort Worth, TX 76102

Date of Event Requiring Statement:             12/11/2020


Name:                                          Bratton Capital, Inc.

Address:                                       201 Main Street, Suite 1900
                                               Fort Worth, TX 76102

Date of Event Requiring Statement:             12/11/2020